INTRODUCTION: Aspirin-intolerant asthma (AIA), a major clinical presentation of aspirin hypersensitivity, affects 10% of adult asthmatics. The genetic risk factors involved in the susceptibility to AIA have recently been investigated, but multilocus single-nucleotide polymorphisms (SNPs) associated with this susceptibility has not been evaluated. METHODS: We examined 246 asthmatic patients: 94 having aspirin intolerance and 152 having aspirin tolerance. We selected 23 SNPs of 13 candidate genes and genotyped each SNP using a primer extension method. Multilocus genetic interactions were examined using multifactor dimensionality reduction (MDR) to test all multilocus SNP combinations to identify a useful SNP set for predicting the AIA phenotype. RESULTS: We identified the best model using the MDR method, which consisted of a four-locus gene-gene interaction with 65.16% balanced accuracy and a cross-validation consistency of 70% in predicting AIA disease risk among asthmatic patients. This model included four SNPs such as B2ADR 46A>G, CCR3-520T>G, CysLTR1-634C>T, and FCER1B-109T>C. DISCUSSION: These results suggest that a multilocus SNP acts in combination to influence the susceptibility to aspirin intolerance in asthmatics and could be a useful genetic marker for the diagnosis of AIA.
INTRODUCTION:Aspirin-intolerant asthma (AIA), a major clinical presentation of aspirinhypersensitivity, affects 10% of adult asthmatics. The genetic risk factors involved in the susceptibility to AIA have recently been investigated, but multilocus single-nucleotide polymorphisms (SNPs) associated with this susceptibility has not been evaluated. METHODS: We examined 246 asthmatic patients: 94 having aspirin intolerance and 152 having aspirin tolerance. We selected 23 SNPs of 13 candidate genes and genotyped each SNP using a primer extension method. Multilocus genetic interactions were examined using multifactor dimensionality reduction (MDR) to test all multilocus SNP combinations to identify a useful SNP set for predicting the AIA phenotype. RESULTS: We identified the best model using the MDR method, which consisted of a four-locus gene-gene interaction with 65.16% balanced accuracy and a cross-validation consistency of 70% in predicting AIA disease risk among asthmatic patients. This model included four SNPs such as B2ADR 46A>G, CCR3-520T>G, CysLTR1-634C>T, and FCER1B-109T>C. DISCUSSION: These results suggest that a multilocus SNP acts in combination to influence the susceptibility to aspirin intolerance in asthmatics and could be a useful genetic marker for the diagnosis of AIA.
Authors: T D Howard; P A Whittaker; A L Zaiman; G H Koppelman; J Xu; M T Hanley; D A Meyers; D S Postma; E R Bleecker Journal: Am J Respir Cell Mol Biol Date: 2001-09 Impact factor: 6.914
Authors: M L Kowalski; A Ptasinska; M Jedrzejczak; B Bienkiewicz; M Cieslak; J Grzegorczyk; R Pawliczak; L Dubuske Journal: Allergy Date: 2005-09 Impact factor: 13.146
Authors: S Higa; T Hirano; M Mayumi; M Hiraoka; Y Ohshima; M Nambu; E Yamaguchi; N Hizawa; N Kondo; E Matsui; Y Katada; A Miyatake; I Kawase; T Tanaka Journal: Clin Exp Allergy Date: 2003-08 Impact factor: 5.018
Authors: K Sladek; R Dworski; J Soja; J R Sheller; E Nizankowska; J A Oates; A Szczeklik Journal: Am J Respir Crit Care Med Date: 1994-04 Impact factor: 21.405
Authors: Kathryn T Hall; Christopher P Nelson; Roger B Davis; Julie E Buring; Irving Kirsch; Murray A Mittleman; Joseph Loscalzo; Nilesh J Samani; Paul M Ridker; Ted J Kaptchuk; Daniel I Chasman Journal: Arterioscler Thromb Vasc Biol Date: 2014-07-17 Impact factor: 8.311